November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
U.S. FDA approved pembrolizumab for NSCLC as single-agent for adjuvant and in combination with chemo for neoadjuvant settings – American Association for Cancer Research
Oct 18, 2023, 16:43

U.S. FDA approved pembrolizumab for NSCLC as single-agent for adjuvant and in combination with chemo for neoadjuvant settings – American Association for Cancer Research

American Association for Cancer Research recently shared on its Twitter page:

“Today, the U.S. FDA approved the immune checkpoint inhibitor pembrolizumab in combination with chemotherapy before surgery and continuation as a single-agent treatment after surgery for some patients with non-small cell lung cancer.”

Source: AACR/Twitter